The drug 5AzaC downregulates the HPV E6 and E7 oncogene expression in cervical cancer and head/neck SCC cell lines, and there is evidence that treatment with 5Aza-C can enhance the potency of the HPV DNA vaccine through the upregulation of CRT/E7 expression and the subsequent enhanced E7-specific CD8+ T cell immune response (4). Here, CD8A is linked to cervical cancer.